News

EVMS and ODU join forces to create state’s largest health sciences program

Old Dominion University and Eastern Virginia Medical School are joining forces in an effort to grow local medical talent where there’s a great public need.

Together EVMS and ODU are now the Macon and Joan Brock Virginia Health Sciences at ODU.

The merger creates the largest health sciences program in the Commonwealth.

Come July 1, the integration will develop a larger pipeline for healthcare professionals in Hampton Roads by attracting and retaining homegrown talent and doubling the number of residency slots.

“All you’ve heard today is to better the community, better health care in the region,” said EVMS President Alfred Abuhamad, “so this is why there’s tremendous excitement on campus with EVMS about coming together with ODU.”

A 10-year agreement with ODU, EVMS and Sentara provides $350 million in total support for the new academic health sciences center. The merger expands healthcare capabilities while reducing disparities in Hampton Roads.

A $20 million endowment from the Ellmer family and a $20 million endowment from the Brock family will provide scholarships for local students who want to go into health sciences but are held back by financial hardship. ODU’s School of Nursing and College of Health Sciences were renamed the Ellmer School of Nursing and Ellmer College of Health Sciences.

“Those scholarships are encouraging students to stay and be here,” said ODU President Brian Hemphill. “Their residencies, our students that are going into nursing and physical therapy, we want them here.”

The integrated Virginia Health Sciences program will collectively serve 5,000 students.

 

Read more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin